Jump Financial LLC Has $1.39 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Jump Financial LLC decreased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 98.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,737 shares of the company's stock after selling 1,960,263 shares during the quarter. Jump Financial LLC's holdings in Ionis Pharmaceuticals were worth $1,389,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in IONS. Everence Capital Management Inc. bought a new position in Ionis Pharmaceuticals in the fourth quarter worth approximately $237,000. Assenagon Asset Management S.A. lifted its stake in shares of Ionis Pharmaceuticals by 967.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 141,917 shares of the company's stock worth $4,961,000 after purchasing an additional 128,619 shares during the last quarter. SG Americas Securities LLC boosted its position in Ionis Pharmaceuticals by 222.5% during the fourth quarter. SG Americas Securities LLC now owns 23,927 shares of the company's stock valued at $836,000 after purchasing an additional 16,508 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Ionis Pharmaceuticals by 19.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,480 shares of the company's stock valued at $1,170,000 after purchasing an additional 5,359 shares during the last quarter. Finally, abrdn plc raised its holdings in Ionis Pharmaceuticals by 32.4% in the fourth quarter. abrdn plc now owns 401,501 shares of the company's stock worth $14,028,000 after purchasing an additional 98,227 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Stock Up 0.3 %

NASDAQ IONS traded up $0.09 during trading hours on Friday, reaching $29.66. 247,592 shares of the company traded hands, compared to its average volume of 1,523,127. The stock has a market capitalization of $4.71 billion, a PE ratio of -9.76 and a beta of 0.29. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $52.34. The company has a 50 day moving average of $30.72 and a two-hundred day moving average of $33.98.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. During the same quarter in the prior year, the firm earned $0.12 EPS. The company's revenue for the quarter was down 30.2% compared to the same quarter last year. As a group, equities analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IONS. Guggenheim restated a "buy" rating on shares of Ionis Pharmaceuticals in a research note on Thursday, April 3rd. BMO Capital Markets dropped their target price on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating on the stock in a research note on Thursday, February 20th. Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. StockNews.com raised shares of Ionis Pharmaceuticals to a "sell" rating in a research report on Tuesday, March 18th. Finally, Citigroup dropped their target price on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $56.72.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CFO Elizabeth L. Hougen sold 1,523 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $32.44, for a total value of $49,406.12. Following the transaction, the chief financial officer now owns 110,500 shares in the company, valued at approximately $3,584,620. This represents a 1.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brett P. Monia sold 13,242 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $32.45, for a total value of $429,702.90. Following the sale, the chief executive officer now owns 219,526 shares of the company's stock, valued at approximately $7,123,618.70. This represents a 5.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,167 shares of company stock valued at $2,010,458 in the last quarter. Insiders own 2.71% of the company's stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.